Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics reports developments as a clinical-stage biopharmaceutical company focused on antibody-drug conjugates for cancers with high unmet medical need. Its news centers on the company’s Dolasynthen and Immunosynthen ADC platforms, including Emi-Le, or emiltatug ledadotin; XMT-1660, a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a HER2 epitope.
Recurring updates include clinical data and trial disclosures for solid-tumor programs, business and financial results, material agreements, shareholder voting matters, governance items, capital-structure actions, and Nasdaq listing-related disclosures.
Mersana Therapeutics (NASDAQ:MRSN) announced an upcoming conference call on August 7, 2020, at 8:00 a.m. ET to discuss its financial results for Q2 2020, ending June 30. The company specializes in developing antibody-drug conjugates (ADCs) for high unmet medical needs in cancer treatment. Mersana's lead candidate, XMT-1536, is advancing through clinical trials for ovarian cancer and non-small cell lung cancer (NSCLC). The company is also progressing with XMT-1592, targeting NaPi2b-expressing tumors. More information is available on their website.
Mersana Therapeutics (NASDAQ: MRSN) presented promising preclinical data on XMT-1592, an antibody-drug conjugate (ADC) targeting NaPi2b, and its Immunosynthen STING-agonist ADC platform at AACR 2020. Key findings include excellent activity, tolerability, and pharmacokinetics of XMT-1592, which is undergoing a Phase 1 study for non-small cell lung cancer and ovarian cancer. Additionally, Immunosynthen demonstrated complete tumor regressions in preclinical models with robust immune memory.
Mersana Therapeutics (MRSN) has closed an underwritten registered public offering of 9,200,000 shares of common stock at $19.00 per share, raising approximately $174.8 million in gross proceeds. The offering involved the exercise of underwriters' options for additional shares. The funds will support Mersana's pipeline of antibody-drug conjugates targeting cancer, including ongoing clinical trials for its lead candidate, XMT-1536. Cowen and SVB Leerink acted as joint bookrunning managers.
Mersana Therapeutics (NASDAQ:MRSN) announced that CEO Anna Protopapas will present at the Jefferies Virtual Global Healthcare Conference on June 3 at 9:00 a.m. ET. The presentation will be available via live webcast on Mersana's website, with an archived replay accessible for 90 days post-event.
Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer treatment. Their leading candidate, XMT-1536, is in a Phase 1 study for ovarian cancer and NSCLC adenocarcinoma. Another ADC, XMT-1592, targets NaPi2b-expressing tumors and is in dose escalation stages.
Mersana Therapeutics (Nasdaq:MRSN) announced plans for an underwritten public offering of 5 million shares of common stock, with a 30-day option for underwriters to purchase an additional 15%. The proceeds will fund clinical development of XMT-1536 and XMT-1592, advance new ADC candidates into Phase 1 trials, and cover general corporate expenses. The offering is conditional and dependent on market conditions. The shares are offered under an effective shelf registration statement filed with the SEC.
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, will present preclinical data for its ADC candidate XMT-1592 and its Immunosynthen STING-agonist ADC platform at the AACR 2020 Virtual Annual Meeting from June 22 to June 24, 2020. Key presentations include:
- XMT-1592: Targeting NaPi2b in ovarian cancer and lung adenocarcinoma (Abstract 7067, Poster 2894)
- STING Agonist ADC: Promoting anti-tumor immune responses (Abstract 6258, Poster 6706)
This reflects Mersana's commitment to developing innovative cancer therapies.
Mersana Therapeutics (NASDAQ:MRSN) announced the start of patient dosing for its Phase 1 dose escalation study of XMT-1592, an antibody-drug conjugate targeting NaPi2b. This study aims to establish the maximum tolerated dose in patients with non-small cell lung cancer (NSCLC) adenocarcinoma and ovarian cancer. XMT-1592 has shown promising preclinical efficacy, particularly a four-fold increase in efficacy over its predecessor, XMT-1536. This advancement marks a significant milestone in Mersana's pipeline development.
Mersana Therapeutics (NASDAQ:MRSN) reported promising results from the Phase 1 dose escalation study of XMT-1536, indicating it is well tolerated without severe side effects typically associated with antibody-drug conjugates. The company raised $65 million through an ATM facility to support ongoing clinical trials. For Q1 2020, Mersana had cash equivalents of $78.4 million and reported a net loss of $16.9 million. The Phase 1 expansion study data will be presented on May 27, 2020, and at the ASCO 2020 virtual conference, with further developments expected from the XMT-1592 program.